A phase II study of docetaxel in chemotherapy-naive patients with recurrent or metastatic adult soft tissue sarcoma

Sarcoma

Volumn 2, Issue 1, 1998, Pages 29-33

  Bramwell, Vivien ^a   Blackstein, Martin ^b   Belanger, Karl ^c   Verma, Shail ^d   Beare, Sandra ^e   Eisenhauer, Elizabeth ^e  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c NOTRE DAME HOSPITAL   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e Institut national du cancer du Canada   (Canada)

Author keywords

Chemotherapy; Docetaxel; Soft tissue sarcoma

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; MALE; METASTASIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOFT TISSUE SARCOMA; TUMOR RECURRENCE;

EID: 0031812631     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577149878136     Document Type: Article

References (19)

1. Van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases. The European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 1996; 77:675-82.
2. Bramwell VHC. Chemotherapy for metastatic soft tissue sarcomas - another full circle? Br J Cancer 1991; 64:7-9.
3. Santoro A, Tursz T, Mouridsen H, et al. A. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas:a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13:1537-45.
4. Tursz T, Verweij J, Judson I, et al. Is high-dose chemotherapy of interest in advanced soft tissue sarcomas (ASTS)? An EORTC randomized phase III trial. Proc Am Soc Clin Oncol 1996; 15:337.
5. Lavelle F, Fizames C, Gueritte-Voegelin F, et al. Experimental properties of RP56976, a taxol derivative. Proc Am Assoc Cancer Res 1989; 30:566.
6. Ringel I, Horwitz SB. Studies with RP56976 (docetaxel): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83:288-91.
7. Bissery MC, Bayssas M, Lavelle F. Preclinical evaluation of intravenous docetaxel RP56976, NSC 628503), a taxol analog. Proc Am Assoc Cancer Res 1990; 31:417.
8. Extra J-M, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53:37-42.
9. McGuire WP, Rowinski EK, Rosenhein NB, et al. Taxol, a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111:273-9.
10. Holmes FA, Frye D, Theriault HL, et al. Phase II study of taxol in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1991; 113.
11. Eisenhauer EA. Docetaxel: current status and future prospects. J Clin Oncol 1995; 13:2865-8.
12. Balcerzak SP, Benedetti J, Weiss GR, et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 1995; 76:2248-52.
13. Waltzman R, Schwartz GK, Shorter S, et al. Lack of efficacy of paclitaxel (Taxol) in patients with advanced soft tissue sarcoma (soft tissue sarcoma). Proc Am Soc Clin Oncol 1996; 15:526.
14. Gian V, Lynch J, McCarley D, et al. Taxol in the treatment of recurrent or metastatic soft tissue or osteosarcomas. Proc Am Soc Clin Oncol 1995; 14:516.
15. Van Hoesel QGCM, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5:539-42.
16. Verweij J, Judson I, Crowther D, et al. Randomized study comparing docetaxel (Taxotere) to doxorubicin (D) in previously untreated soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 1997; 16:496.
17. Van Hoesel OGCM, Verweij J, Clavel M, et al. Phase II study with Taxotere (RP56976) in advanced soft tissue sarcomas of the adult. Eur J Cancer 1993; 29A:183.
18. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994; 30A: 1058-60.
19. Latreille J, Cormier Y, Martins H, et al. Phase II study of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 1996; 13:343-5.